Tranexamic acid or TXA is a systemic antifibrinolytic agent, which inhibits clot breakdown and stems excessive bleeding. This easily administered medicine has been shown to significantly reduce general morbidity and mortality due to bleeding in trauma patients. TXA has the potential to save women’s live in childbirth by decreasing blood loss due to postpartum hemorrhage. TXA is an off-patent, generic medicine made by several companies and costs about $4.50 per gram. The drug is marketed in tablet form as Lysteda and in IV form as Cyklokapron in the U.S., as Transamin in Asia, and as Espercil in South America.